Drug Profile
MDCO 2010
Alternative Names: CU-2010; MDCO-2010Latest Information Update: 17 Jan 2020
Price :
$50
*
At a glance
- Originator Curacyte AG
- Developer The Medicines Company
- Class Antifibrinolytics; Small molecules
- Mechanism of Action Antifibrinolytic agents; Serine protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Surgical blood loss
Most Recent Events
- 06 Jan 2020 The Medicines Company has been acquired by Novartis
- 04 Oct 2012 Discontinued - Phase-II for Surgical blood loss in Germany (IV)
- 04 Oct 2012 Discontinued - Phase-II for Surgical blood loss in Switzerland (IV)